$BLTE News

Full Transcript: Belite Bio Q1 2026 Earnings Call

Belite Bio, Inc (BLTE) Presents at 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - Slideshow

Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215

Belite Bio, Inc 2026 Q1 - Results - Earnings Call Presentation

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript

Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate

Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt Disease

Belite Bio To Present Topline Data From Phase 3 DRAGON Study Of Stargardt Disease Type 1 Treatment At 27th Fundus Disease Forum And International Retinal Symposium

Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Belite Bio, Inc (BLTE) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference - Slideshow

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference Transcript

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

Belite Bio Initiates Rolling Submission Of New Drug Application To FDA For Tinlarebant Oral Therapy To Treat Stargardt Disease Type 1

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference

Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald

Belite Bio, Inc 2025 Q4 - Results - Earnings Call Presentation

Belite Bio Advances Tinlarebant Toward FDA Review After DRAGON Success